Home » Stocks » BIVI

BioVie, Inc. (BIVI)

Stock Price: $15.35 USD 2.15 (16.29%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 213.61M
Revenue (ttm) n/a
Net Income (ttm) -68.84M
Shares Out 13.92M
EPS (ttm) -9.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $15.35
Previous Close $13.20
Change ($) 2.15
Change (%) 16.29%
Day's Open 13.48
Day's Range 13.48 - 15.73
Day's Volume 94,630
52-Week Range 7.50 - 46.10

News

SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver dise...

1 week ago - GlobeNewsWire

About BIVI

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.

Industry
Biotechnology
Founded
2013
Stock Exchange
NASDAQ
Ticker Symbol
BIVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for BioVie stock is "Strong Buy" and the 12-month stock price forecast is 47.00.

Price Target
$47.00
Analyst Consensus: Strong Buy